Viewing Study NCT02321761


Ignite Creation Date: 2025-12-24 @ 1:02 PM
Ignite Modification Date: 2026-02-02 @ 2:11 PM
Study NCT ID: NCT02321761
Status: UNKNOWN
Last Update Posted: 2018-08-08
First Post: 2014-12-17
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Effect of Amantadine Administration on Spatial Functioning Following Traumatic Brain Injury
Sponsor: Loewenstein Hospital
Organization:

Study Overview

Official Title: Effect of Amantadine Administration on Spatial Functioning Following Traumatic Brain Injury
Status: UNKNOWN
Status Verified Date: 2018-08
Last Known Status: RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Amantadine hydrochloride is one of the drugs given at rehabilitation programs to people who suffered Acquired Brain Injury in order to expedite recovery and improve functioning.

A previous study examined the spatially asymmetric allocation of attention in patients with traumatic brain injury (TBI). Patients demonstrated significantly worse performance with leftward than with rightward cross-hemi field shifts of attention. This is reminiscence of neglect patients. This difference was significantly reduced during and following treatment. Our objective is to investigate whether Amantadine Hydrochloride is effective in improving allocation of spatial attention and improving function in people with Traumatic Brain Injury.
Detailed Description: None

Study Oversight

Has Oversight DMC: True
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: